Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

Table 3

The change in mean central retinal thickness from baseline to different time points.

Change in CRT (microns)	Month 3	Month 6	Month 9	Month 12	Last followup
Bevacizumab group	45	69	74	69	72
Ranibizumab group	64	71	60	67	58
P value	0.2	0.8	0.3	0.9	0.2

CRT: central retinal thickness, LogMAR: logarithm of the minimal angle of resolution.